Skip to content
Govbase
Govbase
Congress·In Committee·H.R. 1672

Drug Pricing: Delaying Price Negotiations for Gene Therapies

Maintaining Investments in New Innovation Act

about 1 year ago·View on Congress.gov

Legislative Progress

House
Senate
President
Law

Key Points

  • This bill changes how long certain high-tech medicines can stay on the market before the government can negotiate lower prices for Medicare. It specifically targets 'advanced drug products' that use gene-targeting technology to treat diseases by changing how genes work.
  • Currently, these types of drugs can be chosen for price negotiations after being on the market for 7 years. This bill would push that timeline back to 11 years, giving drug companies an extra four years to sell the medicine at their own chosen price before the government steps in.
  • The goal is to encourage companies to keep inventing new treatments for rare or difficult diseases. Supporters believe that because these drugs are very expensive to create, companies need more time to earn back the money they spent on research and development.
  • The main trade-off is that Medicare and the people who use it might have to wait longer for lower prices on these specific treatments. Because gene therapies are often among the most expensive medicines available, delaying negotiations could keep government healthcare spending higher for a longer period.

Milestones

2 milestones2 actions
Feb 27, 2025House

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Feb 27, 2025

Introduced in House

Source Information

Document Type

Congressional Bill

Official Title

Maintaining Investments in New Innovation Act

Bill NumberHR 1672
Congress119th Congress
ChamberHouse of Representatives
Latest ActionReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Sponsor

Cosponsors

(41)
D: 5R: 36

Analysis generated by AI. Always verify with official sources.